Filing summary
Entity and period: The supplied filing is Angion Biomedica Corp.’s Form 10-K for the fiscal year ended December 31, 2022, filed March 17, 2023. This does not match the request metadata naming Elicio Therapeutics, Inc.; Elicio is discussed as a proposed merger partner, not the reporting company.
Business context and strategic changes
Angion was a clinical-stage biopharmaceutical company developing therapies for fibrotic and other diseases. After terminating the ANG-3070 kidney-disease Phase 2 JUNIPER trial in June 2022 for patient-safety and risk-benefit concerns, it undertook a strategic realignment, suspended clinical development and reduced its workforce. At year-end it had no products approved for sale and no product-sales revenue.
On January 17, 2023, Angion agreed to an all-stock merger with Elicio. If completed, the combined company is expected to focus on Elicio’s lymph-node AMP immunotherapy platform, particularly ELI-002, a therapeutic cancer vaccine targeting mKRAS-driven tumors. Angion’s remaining programs were largely paused or discontinued; ANG-3070 and ROCK2 could potentially proceed if the merger does not close.
Financial performance and liquidity
| Metric | FY 2022 | FY 2021 |
|---|---|---|
| Total revenue | $2.3 million | $28.3 million |
| Research and development expense | $18.1 million | $48.7 million |
| General and administrative expense | $14.6 million | $18.5 million |
| Restructuring and impairment expense | $9.2 million | None |
| Operating loss | $39.6 million | $39.3 million |
| Net loss | $38.8 million | $54.6 million |
| Net loss per share, basic and diluted | $1.29 | $1.93 |
| Net cash used in operating activities | $38.4 million | $52.6 million |
| Cash and cash equivalents at year-end | $50.5 million | $88.8 million |
2022 revenue was license revenue from Vifor Pharma; grant revenue was zero. Revenue fell 91.9%, primarily reflecting the prior-year recognition of Vifor license revenue and completion of the related performance obligations in 2022. R&D expense declined 62.8%, mainly after completion of ANG-3777 trials and workforce reductions. The $9.2 million restructuring and impairment charge included $6.2 million of termination benefits and $3.0 million of lease-related impairment. Lower noncash fair-value losses and interest expense helped reduce net loss year over year, even as operating loss was broadly flat.
At December 31, 2022, total assets were $52.8 million, total liabilities $9.0 million and stockholders’ equity $43.8 million. Liabilities included operating lease obligations and a financing obligation; the filing does not report material conventional borrowings at year-end. Management said existing cash was expected to fund planned operations for at least 12 months after issuance of the financial statements, well into 2024, while noting projections depend on assumptions. The company reported no substantial doubt about its ability to continue as a going concern for that period.
Outlook, risks and unusual items
- Merger and financing: The merger remained pending at the filing date. Failure to close could trigger termination fees of $1.0 million or $2.0 million in specified circumstances, plus up to $0.5 million of expense reimbursement, and could leave Angion needing another transaction or facing cessation of operations. In January 2023, Angion agreed to provide Elicio a bridge loan with up to $12.5 million aggregate principal and a 20% original issue discount; the initial $5.0 million loan was funded, with further funding subject to conditions.
- Pipeline and clinical risk: The JUNIPER kidney trial was terminated on safety grounds, and Angion determined there was no economically viable path in the studied kidney indications. ANG-3070’s development was suspended pending the merger outcome. ANG-3777’s Phase 3 DGF and Phase 2 CSA-AKI studies did not meet their primary endpoints; Angion does not expect further Vifor milestones or royalties under its current plan.
- Financial and operational risk: Angion had three employees as of March 15, 2023, no approved products, and no expected near-term product revenue. Resuming development would require additional funding, hiring and reliance on third-party, in some cases single-source, manufacturers. Nasdaq had notified the company that its share price was below the $1.00 minimum bid requirement; the stated compliance deadline was June 13, 2023, subject to possible additional time under applicable rules.
- Bank exposure: Substantially all cash was held at Silicon Valley Bank, which was closed in March 2023. Angion reported access to its funds after the government’s depositor-protection action and did not anticipate losses, but noted uncertainty around banking-sector stability.
- Related-party lease transaction: In March 2023, Angion agreed to pay related-party NovaPark a $3.03 million termination fee to surrender its Uniondale lease and relinquish its 10% NovaPark interest. The filing says the surrender relieved approximately $3.86 million of rent payments, plus facility fees and utilities.
- Governance and controls: Management said previously identified material weaknesses in internal financial controls were remediated by September 30, 2022 and concluded controls were effective at year-end. The auditor issued an unqualified opinion on the financial statements; it was not engaged to opine on internal-control effectiveness.
Most important facts for investors to verify
- Confirm the intended issuer: the provided filing is Angion’s 2022 Form 10-K, not an Elicio Form 10-K.
- Check the merger’s eventual closing status, consideration and terms, and the final outcome and repayment terms of the Elicio bridge financing.
- Review subsequent cash use and financing needs against management’s stated runway, including the effects of the lease surrender payment and merger-related costs.
- Confirm the resolution of Nasdaq’s minimum-bid deficiency and any resulting effects on listing, liquidity or share count.
- Assess any subsequent changes in pipeline plans, especially whether ANG-3070 or ROCK2 advances, and the consequences of the unsuccessful ANG-3777 trials.